KENNETH D. CHINSKY, M.D. Chest Diseases of Northwestern PA 3580 Peach Street, Suite 103A Erie, PA 16508 www.chestdiseases.yourmd.com Phone: (814) 864-4755 FAX: (814) 864-5430 Email: Sigsbee@aol.com Home Address 5525 Shadybrook Drive and Phone: Erie, PA 16506 (814) 833-4097 Birthdate: 10/06/60 Personal: Employment: Born in St. Louis, MO Married, 3 children. Wife has a master's degree in early childhood special education. Chest Diseases of Northwestern PA Private Practice 7/91-present Education: Undergraduate: University Missouri-Columbia 1978-81 Honors- Freshman Curator's Scholar 1978-79, University Scholar 1979-81, Who's Who Among American College Students 1981 Medical: University Missouri-Columbia 1981-85 Professional: Postgraduate: Internship/Residency-Internal Medicine at The Jewish Hospital of St. Louis 6/85-6/88 Fellowship-Pulmonary and Critical Care Medicine at Washington University Medical Center 7/88-6/91 Attending Physician, Emergency Room at The Jewish Hospital of St. Louis 7/89-6/91 Attending Physician, Medical Intensive Care Unit and Pulmonary Consult services at The Jewish Hospital of St. Louis and John Cochran VA Hospital of St. Louis 7/90-6/91
Page 2 Professional: (cont) Positions held at St. Vincent Health Center Erie, PA: Director, Intensive Care Unit 1991-2011 Chairman, Critical Care Committee 1994-2011 Chairman, Ethics Committee 1999-2006 Chairman, Credentials Committee 2000-2002 Infection Control Committee 1991-present Medical Staff Leadership including Secretary-Treasurer 2003-2004, Vice-President 2004-2006, President 2006-2008 Medical Executive Committee 1994-present Tuberculosis Clinician, Erie County, PA 1991-present Tuberculosis Clinician, Chautauqua County, NY 1996-2010 Licensure and Diplomate, National Board of Medical Examiners Board Certification: 1986 Diplomate, American Board of Internal Medicine 1988 Diplomate, American Board of Internal Medicine: -Pulmonary 1990, recertified 1999 and 2009 -Critical Care Medicine 1991, recertified 1999 and 2009 Pennsylvania license: MD043792L Research: Professional Societies: Comparison of intermittent mandatory ventilation with and without pressure support ventilation for weaning patients from mechanical ventilation. Presented at symposium, "New trends in mechanical ventilation", at 1991 International Conference of American Thoracic Society. Member, Society of Critical Care Medicine Fellow, American College of Chest Physicians Phi Delta Epsilon Medical Fraternity AMA, Pennsylvania Medical Society, Erie County Medical Society Community: WQLN Board of Directors-Public Radio-TV 1998-2008 Various positions including Chairperson 2006-2007
Page 3 Community: (continued) Awards: Invited Reviewer: Sarah Reed Children s Center Board 2008-present Golden Apple for outstanding clinical educator Saint Vincent Health Center 1992, 2000, and 2009 CHEST Am J Infection Cont Publications: 1. Chinsky K. Goodenberger DM: Use of Indium -- labeled white blood cell scan to diagnose cytomegalovirus pneumonia in a renal transplant recipient with a normal chest radiograph. CHEST 1991; 99: 761-63 2. Chinsky KD, St. John RE, Lefrak SS: A randomized, prospective comparison of intermittent mandatory ventilation (IMV) weaning with and without pressure support ventilation (PSV). Amer Rev Respir Dis 1991; 143: A602 3. Chinsky, K. The Best Part of Practice is the Friendship of Patients. Medical Economics. 1999; 76: 198-201 4. Chinsky K. Critical Interactions Man and Machine. CHEST 2001; 119: 996-97 5. Chinsky K. Ventilator-Associated Pneumonia. CHEST 2002; 122: 1883-84 6. Chinsky K. Unlocking an Effective Approach to Ventilator-Associated Pneumonia. Adv Managers Resp Care 2003; 12: 19-20 7. Chinsky K. Getting In: A Primer on Entering Private Practice. Adv Managers Resp Care. 2004; 13: 18-19 8. Chinsky K. The evolving paradigm of hyperglycemia and critical illness. CHEST 2004; 126: 674-676 9. Chinsky K. Varying approaches to tracheostomy. Vive la difference. CHEST 2005; 127: 1083-1085 10. Chinsky K. Bleeding risk and bronchoscopy: In search of the evidence in evidence-based medicine. CHEST 2005; 127: 1875-1877
Page 4 11. Anzueto A, Ferguson G, Feldman G, Seibert A, Chinsky K, Emmett A, Crater G, Crater G, Knobil K, O Dell D, Kalberg C. A Randomized, Double-Blind Trial Comparing the Effect of Fluticasone/Salmeterol 250/50 with Salmeterol on COPD Exacerbations. Abstract accepted at poster session American Thoracic Society 2008 12. Chinsky K. How to Get Started in Research. Adv Managers Resp Care 2008; 17: 32-34 13. Chinsky, K. Challenges in Diagnosing Ventilator-Associated Pneumonia. (podcast) www.rtmagazine.com/podcast/files/20081001.asp Accessed 10/1/08 14. Anzueto A. Ferguson G, Feldman G, Chinsky K, Seibert A, Emmett, A, Knobil K, O Dell D, Kalberg C, Crater G. Effect of Fluticasone Propionate/ Salmeterol (250/50) on COPD Exacerbations and Impact on Patient Outcomes. COPD 2009; 6:320-329 Clinical Research Trials: 1. A Randomized, 12-week, Double-blind, Placebo-controlled, parallel-group Pilot Study to Evaluate the Safety and Additional Efficacy of Adding Cilomilast (ARIFLO) 15 mg. Twice Daily to Treatment with ADVAIR 250/50 Twice Daily in Patients with Chronic Obstructive Pulmonary Disease (COPD) 2. A 52-week, randomized, double-blind, single-dummy, parallel group, multicenter Phase III study comparing the long-term safety of SYMBICORT pmdi 160/4.5 ug x 4 actuations twice daily to SYMBICORT pmdi 160/4.5 ug x 2 actuations twice daily and budesonide HFA pmdi 160 ug x 4 actuations twice daily in adult and adolescent subjects with asthma 3. A Placebo-Controlled Comparison of Efficacy and Safety of the Current US Version of Pulmicort (Budesonide) Turbuhaler and the New Version of Pulmicort Turbuhaler in Asthmatic Adults Currently Treated with Inhaled Steroids 4. A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo and Active Controlled Study of SYMBICORT pmdi Administered Once Daily in Adults and Adolescents with asthma
Kenneth D. Chinsky, MD Page 5 5. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Determine the Efficacy of Oral Zafirlukast (ACCOLATE ) When Administered According to Current Labeling Instructions or Simplified Dosing Instructions in Subjects With Asthma Receiving Inhaled B2-Agonist in Combination With Inhaled Corticosteroids (ICS) 6. A Randomized, Double-Blind, Double-Dummy, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Oral SB-265805 320 mg. Once Daily for 7 Days Versus Oral Levofloxacin 500 mg. Once Daily for 7 Days for the Treatment of Acute Exacerbation of Chronic Bronchitis 7. A Randomized, Double-Blind, Multicenter Comparison of the Efficacy and Safety of Grepafloxacin (Raxar ) in the Treatment of Patients with Community Acquired Pneumonia 8. A 12-Week, Randomized, Double-Blind, Positive Control, Crossover Study of Albuterol, Ipratropium, and the Combination, as an Inhalation Solution in Patients with Chronic Obstructive Pulmonary Disease 9. A Long Term Safety Study of Levalbuterol and Racemic Albuterol in Subjects Twelve Years of Age and Older with Asthma 10. A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO (15 mg BID) in Patients with Chronic Obstructive Pulmonary Disease (COPD) 11. A Randomized, Double-Blind, Parallel Group, 52-week Study to Compare the Effect of the Fluticasone Propionate/Salmeterol Diskus Combination Product 250/50 mcg BID with Salmeterol Diskus 50 mcg BID on the Annual Rate of Moderate/Severe Exacerbations in Subjects with COPD 12. A 6-Month Double-blind, Double-dummy, Randomized, Parallel group, Multicenter Efficacy and Safety Study of Symbicort pmdi 2 x 160/4.5 mg bid and 2 x 80/4.5 mg bid Compared to Formoterol TBH, Budesonide pmdi (& the combination) & Placebo in COPD patients 13. A Double-Blind, Randomized, Placebo-Controlled, Multicenter, 30-Night Polysomnographic Study of MK-0928 in Elderly Patients with Primary Insomnia 14. A Double-Blind, Randomized, Placebo-Controlled, Multicenter, 30-Night Polysomnographic Study of MK-0928 in Adult Patients with Primary Insomnia
Page 6 15. A Randomized, Double-Blind Trial Comparing the Effect of Fluticasone/Salmeterol 250/50 with Salmeterol on COPD Exacerbations 16. A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg. BID and Fluticasone Propionate (FP) DISKUS 250 mcg. BID in Treatment of Subjects with Asthma 17. A 26-week treatment, multi center, randomized, double-blind, double dummy, placebo-controlled, adaptive, seamless, parallel-group study to assess the efficacy, safety and tolerability of two doses of indacaterol (selected from 75, 150, 300 & 600 ug o.d.) in patients with chronic obstructive pulmonary disease using blinded formoterol (12 ug b.i.d.) and open label tiotropium (18 ug o.d.) as active controls. (Protocol No.: CQAB149B2335S) 18. A 12-week treatment, multi center, randomized, double-blind, placebo controlled, parallel group study to assess the efficacy and safety of indacaterol (150 ug o.d.) in patients with chronic obstructive pulmonary disease. (Protocol No.: CQAB149B2346) 19. A Phase IIb clinical trial to evaluate the safety, tolerability and immunogenicity of Zoster vaccine in patients on chronic/maintenance corticosteroids. (Protocol No.: V211-017) 20. A randomized, double-blind, parallel group 12-week comparison of the efficacy and safety of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a metered-dose-inhaler 230/42 mcg twice-daily with Fluticasone Propionate/Salmeterol DISKUS 250/50 mcg twice-daily in subjects with COPD. (Protocol No.: ADC 111117) 21. A double-blind, randomized, placebo-controlled, multi center, parallel group, dose-ranging study of MK-0633 in adult patients with Chronic Asthma (Protocol No.: 007-010) 22. A 52-week, randomized, double-blind, parallel-group study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Treatment of Subjects with Asthma (Protocol: ADA109057)
Page 7 23. A multicenter, randomized, double-blind, placebo-controlled, parallel group, 4- week study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of repeat inhaled doses of the Combination of GSK233705 and GW642444 administered once-daily in Subjects With COPD (Protocol: DB1111581) 24. A randomized, double-blind, parallel-group, 24-week study to evaluate the efficacy and safety of ADVAIR DISKUS (Fluticasone Propionate/Salmeterol Combination Product 250/50 mcg Inhalation Powder) BID plus Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder 18mcg) QD versus Spiriva QD plus Placebo DISKUS BID in Subjects with Chronic Obstructive Pulmonary Disease (COPD) (Protocol: ADC111114) 25. A randomized, double-blind, controlled, parallel group, 12 week treatment study to compare the efficacy and safety of the combination of indacaterol 150 µg once daily with open label tiotropium 18µg once daily versus open label tiotropium 18µg once daily in patients with moderate-to-severe chronic obstructive pulmonary disease (Protocol No.: CQAB149B2351) 26. Efficacy and safety of aclidinium bromide at two dose levels (200 µg twice daily, 400µg twice daily) vs. placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD) (Protocol: LAS-MD-33) 27. A Long-term, Randomized, Double-Blind, Extension Study of the Safety, Tolerability and Efficacy of Aclidinium Bromide at Two Dose Levels When Administered to Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (Protocol: LAS-MD-36) 28. A randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of 2 doses of aclidinium bromide compared with placebo for 12 weeks in patients with moderate to severe, stable chronic obstructive pulmonary disease followed by a 40-week evaluation of the 2 aclidinium bromide doses (Protocol LAS-MD-38) 29. Validation of a New Shortness of Breath with Daily Activities Questionnaire in patients with Chronic Obstructive Pulmonary Disease (ASQ112989) 30. Novartis Pharmaceuticals trial entitled: A randomized, double-blind, doubledummy, placebo-controlled, parallel-group study to assess the efficacy and safety of different doses of indacaterol in adult patients with persistent asthma, using salmeterol as an active control.cqab149b2357
Page 8 31. Novartis Pharmaceuticals trial entitled: A 26-week treatment multicenter, randomized, double-blind, parallel-group, placebo and active controlled (open label) study to assess the efficacy, safety and tolerability of QVA149 (110/50 mcg q.d.) in patients with moderate to severe chronic obstructive pulmonary disease (COPD). QVA149A2303 32. A 52-week treatment, multi-center, randomized, double-blind, parallel-group, active controlled study to evaluate the effect of QVA149 (110/50 μg o.d.) vs NVA237 (50 μg o.d.) and open-label tiotropium (18 μg o.d.) on COPD exacerbations in patients with severe to very severe chronic obstructive pulmonary disease (COPD). CQVA149A2304 33. A randomized, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution delivered by the Respimat Inhaler with Tiotropium inhalation capsules 18 µg delivered by the HandiHaler. 205.452 34. A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo- Controlled Study to Evaluate the Safety and Tolerability of GSK573719 125mcg once-daily alone and in combination with GW642444 25mcg once-daily via novel Dry Powder Inhaler (ndpi) in Subjects with Chronic Obstructive Pulmonary Disease (COPD). DB2113359 35. A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily via a Novel Dry Powder Inhaler in Subjects with Chronic Obstructive Pulmonary Disease: DB2113373. 36. A Phase III, Randomized, Double-blind, Placebo-Controlled Study Evaluating The Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo for 24- Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD): LAC-MD-31.
Page 9 37. A Long-Term, Randomized, Study of the Safety and Tolerability of a Fixed-Dose Combination of Aclidinium Bromide/Formoterol Fumarate compared with Formoterol Fumarate in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD): LAC-MD-32. 38. A 52-week, double-blind, randomized, placebo controlled parallel group study to evaluate the effect of roflumilast 500 μg on exacerbations in severe to very severe COPD patients treated with fixed dose combination LABA/ICS (Advair 250/50 μg or, Symbicort 160/4.5 μg): ROF-MD-07. 39. A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or an increased risk for cardiovascular disease: HZC113782 - SUMMIT. 40. Novartis Pharmaceuticals trial entitled: A randomized, placebo-controlled, doseranging, multi-centre trial of QAW039 (1-450 mg p.o.) to investigate the effect on FEV 1 in and ACQ patients with moderate-to-severe, persistent, allergic asthma, inadequately controlled with ICS therapy: CQAW039A2206. 41. A Phase III, Long-Term, Randomized, Double-Blind, Extension Study of the Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients with Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD): LAC-MD-36. 42. A randomized, double blind, parallel group study to assess the efficacy and safety of 12 weeks of once daily, orally inhaled, co-administration of olodaterol 5µg (delivered by the Respimat Inhaler) and tiotropium 18µg (delivered by the HandiHaler ) compared to once daily, orally inhaled, co-administration of placebo (delivered by the Respimat Inhaler) and tiotropium 18µg (delivered by the HandiHaler ) in patients with Chronic Obstructive Pulmonary Disease (COPD): 1222.51 revised 1/13